BMS has welcomed the recently announced listing of immunotherapy combination OPDIVO (nivolumab) in combination with YERVOY (ipilimumab) for the treatment of advanced renal cell carcinoma. …
Latest Video
New Stories
-
PM: Look beyond 'corporate interests' on policy
August 20, 2019 - - Latest News -
Is the policy-implementation split really that simple?
August 20, 2019 - - Comment -
Sanofi partners on new insulin service
August 20, 2019 - - Latest News -
PAGE co-founders on its creation, achievements and personal reflections
August 19, 2019 - - BioPharmaDispatch Executive -
BioPharmaDispatch launches podcasts
August 19, 2019 - - Latest News -
Sanofi hosts students for National Science Week
August 19, 2019 - - Latest News -
Industry secures PSD redaction extension after intervention
August 19, 2019 - - Latest News